Monoclonal antibody (mAb)-based therapeutics are playing an increasingly important role in
the treatment or prevention of many important diseases such as cancers, autoimmune …

Monoclonal antibodies (mAbs) are a fast-growing class of biopharmaceuticals. They are
widely used in the identification and detection of cell makers, serum analytes, and …

Monoclonal antibodies (MAs) are complex biotherapeutics as their molecular mechanism of
action depends on multiple domains. Consequently regulatory approval of biosimilars of …

The development of new monoclonal antibodies (mAbs) is a still evolving field in finding new
therapeutics. Structurally, mAbs have evolved over the past years by change from fully …

Biological drugs and their originated biosimilars are large, highly complex molecules
derived from living cells or organisms. Traditional medicines, by contrast, are usually simple …

It has been over four decades since the development of monoclonal antibodies (mAbs)
using a hybridoma cell line was first reported. Since then more than thirty therapeutic …

To the Editor—The debate concerning biosimilar monoclonal antibodies (mAbs) has
matured over the past 10 years. During the early 2000s, it centered on (i) whether …

Objective: The aim was to critically evaluate well-established regulatory agencies mAb
biosimilar guidelines for development and marketing authorization about quality, efficacy …

Toward biosimilar monoclonal antibodies | Nature Biotechnology Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …

The concept of biosimilar was established in the early 2000s in EU. Currently, the regulatory
framework for biosimilar has also been established in the US, Japan, and other countries. As …